Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Romanian Agency Reorganizes To Boost Performance & Face Brexit Challenge

Executive Summary

The Romanian medicines agency is to be reorganized to improve the way it works and allow it to take on more work as a result of Brexit. One consequence is that industry fees may have to rise to pay for this work as well as a sharp rise in staff numbers.

You may also be interested in...



Ireland Embarks On New Stage Of Drug Verification System

The bedding-in period is ending for Europe’s one-year-old system for preventing the circulation of fake medicines, and the scheme is gearing up for a more fully operational stage. 

EU & US At Odds Over Merck’s Keytruda

EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.

First African Approvals For Merck’s Ebola Vaccine

Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa. 

Topics

UsernamePublicRestriction

Register

PS140665

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel